Home | Articles
Published on:June 2022
Indian Journal of Pharmaceutical Education and Research, 2022; 56(3):636-645
Review Article | doi:10.5530/ijper.56.3.112

Interstitial Cystitis-Critical Assessment of Current Treatment and Opportunities for Nanodelivery


Authors and affiliation (s):

Afzal Haq Asif1, Anroop Nair2, Bandar Aldhubiab2, Sreeharsha Nagaraja2,3,*, Girish Meravanige4, Syed Mohammed Basheeruddin Asdaq5, Md. Khalid Anwer6, Arshia Shariff3, Syed Dawood Noor7

1Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, SAUDI ARABIA.

2Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, KSA.

3Department of Pharmaceutics, Vidya Siri College of Pharmacy, Off Sarjapura Road, Bangalore, Karnataka, INDIA.

4Department of Biomedical Sciences, College of Medicine, King Faisal University, Al-Ahsa, SAUDI ARABIA.

5Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh, SAUDI ARABIA.

6Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Alkharj, SAUDI ARABIA.

7Department of Pharmacognosy, Vidya Siri College of Pharmacy, Off Sarjapura Road, Bangalore, Karnataka, INDIA.

Abstract:

The characteristic feature of Interstitial cystitis (IC) or bladder pain syndrome is augmented, pressure, or inconvenience in the suprapubic or bladder region. The causative factors for IC are not completely understood however certain underlying disease condition may trigger the pain. The therapy is aimed to provide symptomatic relief, and therefore, the treatment protocols have been established based on experience. Intravesical delivery of drugs has been well explored and found to be most effective in minimizing the symptoms of IC without systemic adverse events. However, the efficacy of drug absorption is limited by the bladder wall permeability and poor absorption of the instilled drugs. The intravesical approach should be coupled with novel nanocarriers such as nanoparticles or liposomes to overcome these limitations. Nanoparticles can easily cross the bladder permeability barrier and enhance the drug retention time in the bladder, making the delivery efficient and promising. This review addresses the current IC management strategies, new potential therapeutic agents of natural origin, and various drugs undergoing clinical trials by different routes of administration.

Keywords: IC, Bladder pain syndrome, Bladder permeability barrier, Intravesical delivery, Nanotherapeutics.

 




 

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the Latest Release of Journal Citation Reports (source: Web of Science Data).

 

Impact Factor® as reported in the 2023 Journal Citation Reports® (Clarivate Analytics, 2023): 0.8

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs